Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TFF Pharmaceuticals, Inc.    TFFP

TFF PHARMACEUTICALS, INC.

(TFFP)
  Report
Delayed Quote. Delayed Nasdaq - 12/02 04:00:01 pm
15.33 USD   -1.98%
11/24TFF PHARMACEUTICALS : Corporate Presentation
PU
11/19TFF PHARMACEUTICALS : Corporate Presentation
PU
11/13TFF PHARMACEUTICALS : Corporate Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

TFF Pharmaceuticals : Corporate Presentation

08/26/2020 | 12:51pm EST

Advanced Technology for Better Drug Delivery Options

M a y 2 0 2 0 C o r p o r a t e I n v e s t o r P r e s e n t a t i o n

SAFE HARBOR STATEMENT

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements concerning TFF Pharmaceuticals, Inc. ("TFF", the "Company," "we," "us," and "our"). The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. These forward- looking statements include, but are not limited to, statements concerning the following:

  • our future financial and operating results;
  • our intentions, expectations and beliefs regarding anticipated growth, market penetration and trends in our business;
  • the timing and success of our plan of commercialization;
  • our ability to successfully develop and clinically test our product candidates; and
  • our ability to file for FDA approval of our product candidates through the 505(b)(2) regulatory pathway.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially. Among those factors are: (i) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (ii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform and (iii) those other risks disclosed in the section "Risk Factors" included in the Company's 2019 Annual Report on Form 10-K filed March 26, 2020 with the SEC. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

This document contains only basic information concerning TFF. Because it is a summary it does not contain all of the information you should consider before investing. Please refer to our reports and registration statements on file with the SEC for more comprehensive information concerning TFF Pharmaceuticals.

2

COMPANY OVERVIEW

  • The company's Thin Film Freezing platform converts poorly absorbed drugs into inhalable dry powder formulations, targeting multiple $Billion-plus markets
  • Expects two NDA filings within 28 months at a clinical and development cost of approx. $27MM
  • CEO Glenn Mattes - experienced pharma industry executive (Centocor, Johnson & Johnson, Rhone-Poulenc Rorer)
  • Two product candidates under development and several strategic business development opportunities underway
  • Robust IP estate - including 41 patents issued and/or pending

3

TFF LEADERSHIP

GLENN MATTES

President & Chief Executive Officer

  • 30 years of business leadership experience in development and commercial launches of global therapeutics
  • Former CEO of Tibotec Therapeutics, a J&J company, and Rhone-Poulenc Rorer/Canada, and in addition to other senior C-suite positions at Centocor and J&J
  • Critical roles in launch of J&J's first two HIV/AIDS therapeutics, as well as other drugs Doxil, Procrit,
    Remicade, Taxotere and Lovenox
  • Appointed to the President's Advisory Council on HIV/AIDS by President George W. Bush and the US Secretary of Health and Human Services

BOARD OF DIRECTORS

Highly experienced healthcare and life science finance executives

  • Former CEOs, Institutional fund founder and Board-level roles
  • Deep functional experience in all areas of healthcare companies
  • Commercially successful enterprises
  • Track record of numerous significant exits and transactions

PREVIOUS EXPERIENCE

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

TFF Pharmaceuticals Inc. published this content on 26 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 August 2020 16:51:00 UTC


© Publicnow 2020
All news about TFF PHARMACEUTICALS, INC.
11/24TFF PHARMACEUTICALS : Corporate Presentation
PU
11/19TFF PHARMACEUTICALS : Corporate Presentation
PU
11/13TFF PHARMACEUTICALS : Corporate Presentation
PU
11/12TFF PHARMACEUTICALS : Corporate Presentation
PU
11/12TFF PHARMACEUTICALS : to Present at the Jefferies Virtual London Healthcare Conf..
BU
11/05TFF PHARMACEUTICALS : Note 2 - liquidity and management's plans
AQ
11/05TFF PHARMACEUTICALS : Reports Third Quarter 2020 Financial and Business Results
BU
11/05TFF PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Finan..
AQ
11/05TFF PHARMACEUTICALS : Corporate Presentation
PU
11/05TFF PHARMACEUTICALS : and Felix Biotechnology Sign Letter of Intent for a Collab..
BU
More news
Financials (USD)
Sales 2020 0,50 M - -
Net income 2020 -17,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -18,0x
Yield 2020 -
Capitalization 341 M 341 M -
Capi. / Sales 2020 681x
Capi. / Sales 2021 48,3x
Nbr of Employees 4
Free-Float 75,1%
Chart TFF PHARMACEUTICALS, INC.
Duration : Period :
TFF Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TFF PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 20,50 $
Last Close Price 15,33 $
Spread / Highest target 50,0%
Spread / Average Target 33,7%
Spread / Lowest Target 17,4%
EPS Revisions
Managers
NameTitle
Glenn R. Mattes President, Chief Executive Officer & Director
Aaron G. L. Fletcher Chairman
Christopher Cano Chief Operating Officer & VP-Business Development
Kirk Coleman Chief Financial Officer
Brian J. Windsor Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TFF PHARMACEUTICALS, INC.186.54%341
MODERNA, INC.631.08%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.91.71%41 539
IQVIA HOLDINGS INC.10.05%32 829
SEAGEN INC.54.94%31 988